Recent Updates
Recently added Catalysts
SNDL Neutral Sentiment Score: 45/100

SNDL Inc. Condensed Consolidated Interim Financial Statements For the three months ended

Key Takeaway: SNDL Inc. has released its condensed consolidated interim financial statements for the three months ended March 31, 2026. The company reported a decrease in net revenue and an increased operating loss compared to the same period last year. Additionally, the accumulation of shareholder equity showed only a slight improvement in the company's financial position. The overall performance reflects ongoing challenges in managing costs and generating revenue.

Market Sentiment Analysis

CONCERNS & RISKS

  • Net revenue decreased from CAD 204,914 to CAD 195,906 compared to the prior year.
  • Operating loss increased from CAD 12,053 to CAD 9,114, indicating ongoing financial challenges.
  • Accumulated deficit decreased less dramatically, from CAD 1,302,441 to CAD 1,282,860.

Full Press Release Details

Condensed Consolidated Interim Financial Statements
For the three months ended March 31, 2026
(Unaudited expressed in thousands of Canadian dollars)
Condensed Consolidated Interim Statements of Financial Position
(Unaudited - expressed in thousands of Canadian dollars)
As at Note March 31, 2026 December 31, 2025
Assets
Current assets
Cash and cash equivalents 213,404 252,243
Restricted cash 20,124 20,081
Marketable securities 139 84
Accounts receivable 29,059 27,643
Biological assets 6 2,969 3,120
Inventory 7 134,982 126,877
Prepaid expenses and deposits 15,158 15,566
Investments 12 362 484
Assets held for sale 746 746
Net investment in subleases 10 2,877 2,775
419,820 449,619
Non-current assets
Long-term deposits and receivables 2,508 4,526
Right of use assets 8 136,852 138,353
Property, plant and equipment 9 149,398 151,900
Net investment in subleases 10 11,244 11,643
Intangible assets 11 57,824 58,520
Investments 12 14,322 11,574
Equity-accounted investees 13 395,411 385,534
Goodwill 127,260 124,248
Total assets 1,314,639 1,335,917
Liabilities
Current liabilities
Accounts payable and accrued liabilities 51,799 56,747
Lease liabilities 14 34,990 35,462
86,789 92,209
Non-current liabilities
Lease liabilities 14 133,381 134,471
Other liabilities 6,925 8,041
Total liabilities 227,095 234,721
Shareholders' equity
Share capital 15(b) 2,274,393 2,310,398
Warrants 306 306
Contributed surplus 53,089 54,038
Accumulated deficit (1,282,860 ) (1,302,441 )
Accumulated other comprehensive income ( AOCI ) 42,616 38,895
Total shareholders' equity 1,087,544 1,101,196
Total liabilities and shareholders' equity 1,314,639 1,335,917
Commitments and contingencies (note 23)
See accompanying notes to the condensed consolidated interim financial statements.
Condensed Consolidated Interim Statements of Loss and Comprehensive Loss
(Unaudited - expressed in thousands of Canadian dollars, except per share amounts)
Three months ended March 31
Note 2026 2025
Net revenue 17 195,906 204,914
Cost of sales 7 143,094 148,273
Gross profit 52,812 56,641
Investment income 18 1,537 2,856
Share of profit (loss) of equity-accounted investees 13 501 (4,457 )
General and administrative 46,607 46,359
Sales and marketing 4,009 3,767
Depreciation and amortization 8,9,11 12,855 13,228
Share-based compensation 16 616 1,388
Restructuring costs 172 326
Asset (reversal) impairment, net 8,9 (178 ) 1,984
Other income (81 )
Research and development 4 100
Gain on disposition of assets (40 ) (59 )
Operating loss (9,114 ) (12,053 )
Other expenses, net 19 (2,294 ) (2,654 )
Loss before income tax (11,408 ) (14,707 )
Income tax recovery 1,497
Net loss (9,911 ) (14,707 )
Equity-accounted investees - share of other comprehensive income (loss) 13 5,013 (348 )
Investments at fair value through other comprehensive income ( FVOCI ) - change in fair value 12 (1,292 ) (5,230 )
Comprehensive loss (6,190 ) (20,285 )
Net loss per common share attributable to owners of the Company
Basic and diluted 21 $ (0.04 ) $ (0.06 )
See accompanying notes to the condensed consolidated interim financial statements.
Condensed Consolidated Interim Statements of Changes in Shareholders' Equity
(Unaudited - expressed in thousands of Canadian dollars)
Accumulated other comprehensive income
Note Share capital Warrants Contributed surplus Accumulated deficit Equity-accounted investees Investments at FVOCI Total
Balance at December 31, 2025 2,310,398 306 54,038 (1,302,441 ) 31,673 7,222 1,101,196
Net loss (9,911 ) (9,911 )
Other comprehensive income (loss) 5,013 (1,292 ) 3,721
Share repurchases 15(b) (38,760 ) 29,492 (9,268 )
Share-based compensation 16 1,806 1,806
Employee awards exercised 2,755 (2,755 )
Balance at March 31, 2026 2,274,393 306 53,089 (1,282,860 ) 36,686 5,930 1,087,544
Balance at December 31, 2024 2,346,728 667 57,156 (1,323,965 ) 50,906 1,864 1,133,356
Net loss (14,707 ) (14,707 )
Other comprehensive loss (348 ) (5,230 ) (5,578 )
Share repurchases (51,714 ) 36,383 (15,331 )
Share-based compensation 16 2,459 2,459
Employee awards exercised 93 (93 )
Balance at March 31, 2025 2,295,107 667 59,522 (1,302,289 ) 50,558 (3,366 ) 1,100,199
See accompanying notes to the condensed consolidated interim financial statements.
Condensed Consolidated Interim Statements of Cash Flows
(Unaudited - expressed in thousands of Canadian dollars)
Three months ended March 31
Note 2026 2025
Cash provided by (used in):
Operating activities
Net loss for the period (9,911 ) (14,707 )
Adjustments for:
Income tax recovery (1,497 )
Interest and fee income 18 (1,482 ) (2,856 )
Change in fair value of biological assets 6 (46 ) (1,447 )
Change in fair value of inventory sold 230 336
Share-based compensation 16 616 1,388
Depreciation and amortization 8,9,11 14,116 14,187
Gain on disposition of assets (40 ) (59 )
Inventory impairment and obsolescence 7 1,446 591
Finance costs, net 19 2,062 1,690
Change in estimate of fair value of derivative warrants (12 )
Unrealized foreign exchange (gain) loss (299 ) 13
Asset (reversal) impairment, net 8,9 (178 ) 1,984
Share of (profit) loss of equity-accounted investees 13 (501 ) 4,457
Unrealized gain on marketable securities 18 (206 )
Additions to marketable securities 151
Interest received 1,361 2,936
Exercise of cash-settled deferred share units 16(d) (474 )
Change in non-cash working capital 3,20 (1,867 ) (713 )
Net cash provided by operating activities 3,481 7,788
Investing activities
Additions to property, plant and equipment 9 (2,638 ) (1,588 )
Additions to investments 12 (4,032 ) (8,997 )
Principal payments from investments 12 116 26,907
Capital (contributions) distributions from equity-accounted investees 13 (2,866 ) 719
Proceeds from disposal of property, plant and equipment 43 113
Acquisitions 4 (2,900 )
Change in non-cash working capital 20 911 18
Net cash (used in) provided by investing activities (11,366 ) 17,172
Financing activities
Payments on lease liabilities, net 10,14 (10,056 ) (7,512 )
Repurchase of common shares 15(b) (9,575 ) (15,031 )
Change in non-cash working capital 20 819 91
Net cash used in financing activities (18,812 ) (22,452 )
Change in cash and cash equivalents (26,697 ) 2,508
Adjustment on initial application of amendments to IFRS 9 on January 1, 2026 (12,142 )
Cash and cash equivalents, beginning of period 252,243 218,359
Cash and cash equivalents, end of period 213,404 220,867
See accompanying notes to the condensed consolidated interim financial statements.
Notes to the Condensed Consolidated Interim Financial Statements
For the three months ended March 31, 2026
(Unaudited, expressed in thousands of Canadian dollars, except where otherwise noted)
1.Description of business
SNDL Inc. ( SNDL or the Company ) was incorporated under the Business Corporations Act (Alberta) on August 19, 2006.
The Company's head office is located at 101, 17220 Stony Plain Road NW, Edmonton, Alberta, Canada, T5S 1K6.
The principal activities of the Company are the retailing of wines, beers and spirits, the operation and support of corporate-owned, controlled and franchised retail cannabis stores in certain Canadian jurisdictions where the private sale of adult-use cannabis is permitted, the manufacturing of cannabis products providing proprietary cannabis processing services, the production, distribution and sale of cannabis in Canada and for export pursuant to the Cannabis Act (Canada) (the Cannabis Act ), and the deployment of capital to investment opportunities. The Cannabis Act regulates the production, distribution, and possession of cannabis for both medical and adult-use access in Canada.
SNDL and its subsidiaries operate solely in Canada. Through its joint venture, SunStream Bancorp Inc. ( SunStream ) (note 13), the Company provides growth capital that pursues indirect investment and financial services opportunities in the cannabis sector, as well as other investment opportunities. The Company also makes strategic portfolio investments in debt and equity securities.
The Company's liquor retail operations are seasonal in nature. Accordingly, sales will vary by quarter based on consumer spending behaviour. The Company is able to adjust certain variable costs in response to seasonal revenue patterns; however, costs such as occupancy are fixed, causing the Company to report a higher level of earnings in the third and fourth quarters. This business seasonality results in quarterly performance that is not necessarily indicative of the year's performance. The cannabis industry is a growing industry and the Company has not observed significant seasonality as of yet.
The Company's common shares trade on the Nasdaq Capital Market under the ticker symbol SNDL and on the Canadian Securities Exchange under the symbol SNDL .
In early 2025, the U.S. administration imposed certain tariffs on imports from certain countries, including Canada, and in response, the Canadian administration imposed their own tariffs on certain imports from the United States. Canada and the United States continue ongoing negotiations on a new trade and security relationship, though the scope and terms of such negotiations and the agreements they may produce, if any, are unknown. These tariff announcements and the risk of further potential retaliatory tariffs have created uncertainty, which has permeated the economic and investment outlook, impacting current economic conditions, including such issues as the inflation rate and the global supply chain. Aside from the impact on the global economy, these tariffs may continue to impact SNDL.
SNDL is continuing to monitor the evolving situation and the impacts and potential consequences on its financial position. The Company did not experience a significant impact to its financial performance during the three months ended March 31, 2026.
2.Basis of presentation
Statement of compliance
These condensed consolidated interim financial statements ( financial statements ) have been prepared in accordance with International Accounting Standard 34 Interim Financial Reporting as issued by the International Accounting Standards Board and interpretations of the International Financial Reporting Interpretations Committee. These financial statements were prepared using the same accounting policies and methods as those disclosed in the
Notes to the Condensed Consolidated Interim Financial Statements
For the three months ended March 31, 2026
(Unaudited, expressed in thousands of Canadian dollars, except where otherwise noted)
annual consolidated financial statements for the year ended December 31, 2025. These financial statements should be read in conjunction with the annual consolidated financial statements for the Company for the year ended December 31, 2025.
Certain prior period amounts have been reclassified to conform to current year presentation. Specifically, changes to investments have been separated into additions to investments and principal payments from investments and change in fair value of biological assets has been separated into change in fair value of biological assets and change in fair value of inventory sold, both on the condensed consolidated interim statement of cash flows.
These financial statements were approved and authorized for issue by the board of directors of the Company (the Board ) on April 28, 2026.
3.NEW ACCOUNTING STANDARDS
Classification and Measurement of Financial Instruments Amendments to IFRS 9 and IFRS 7
On January 1, 2026, the Company adopted the amendments to IFRS 9 and IFRS 7 using the prospective application. The amendments include the following:
-Clarification on the date of recognition and derecognition of some financial assets and liabilities, with a new exception for some financial liabilities settled through an electronic payment system.
-Clarification and further guidance for assessing whether a financial asset meets the solely payments of principal and interest criterion.
-New disclosure requirements for certain instruments without contractual terms that can change cash flows.
-Updates to the disclosure required for equity instruments designated at FVOCI.
At March 31, 2026, there was a $5.7 million net reduction in cash and cash equivalents with an equivalent increase in accounts receivable, which is reflected in the statement of financial position and statement of cash flows. The Company estimated the impact to be approximately $12.1 million net reduction in cash and cash equivalents with an equivalent increase in accounts receivable, had the amendments been in effect for the annual period ending December 31, 2025.
4.Business acquisitions
On April 9, 2025, the Company announced that it had entered into an arrangement agreement (the 1CM Agreement ) with 1CM Inc. ( 1CM ) pursuant to which it would acquire 32 cannabis retail stores (the 1CM Transaction ) operating under the Cost Cannabis and T Cannabis banners in Ontario, Alberta and Saskatchewan (the 1CM Stores ).
Under the terms of the 1CM Agreement, the Company would acquire, with the option to assign, the 1CM Stores for total consideration of $32.2 million cash, subject to certain adjustments at the closing of the 1CM Transaction. The 1CM Stores are comprised of 2 stores in Alberta, 3 stores in Saskatchewan and 27 stores located in Ontario.
The 1CM Transaction is to be completed by way of an arrangement under the Business Corporations Act (Ontario). On June 16, 2025, 1CM announced the approval of the 1CM Transaction by 1CM shareholders. On June 18, 2025, 1CM announced that the Ontario Superior Court of Justice (Commercial List) approved the plan of arrangement involving SNDL.
On December 15, 2025, the Company announced that it had entered into an amended and restated arrangement agreement (the 1CM A&R Agreement ). Under the 1CM A&R Agreement, the parties have agreed to, among other things, complete the 1CM Transaction in two stages to align with the status of required provincial regulatory approvals. The aggregate purchase price for the 1CM Transaction has not been amended.
Notes to the Condensed Consolidated Interim Financial Statements
For the three months ended March 31, 2026
(Unaudited, expressed in thousands of Canadian dollars, except where otherwise noted)
On January 7, 2026, the first closing ( First Closing ) was completed and involved the purchase of 5 cannabis retail stores located in Alberta and Saskatchewan. The purchase price for the First Closing was $5.0 million cash, subject to certain adjustments at the time of the First Closing. Pursuant to the 1CM A&R Agreement, the Company had previously paid a $2.0 million non-refundable cash deposit towards the purchase price in respect of the First Closing.
The second closing ( Second Closing ) will involve the purchase of the remaining 27 cannabis retail stores, each of which are located in Ontario. The purchase price for the Second Closing will be $27.2 million cash, subject to certain adjustments at the time of the Second Closing. In addition, the outside date for completion of the 1CM Transaction has been extended from December 31, 2025 to May 31, 2026. The previously paid $1.0 million cash deposit from April 2025 will be applied towards the purchase price in respect of the Second Closing, which is still pending regulatory approval.
The purchase price allocation is not final as the Company continues to obtain and verify information required to determine the fair value of certain assets and liabilities and the amount of deferred income taxes, if any, arising on their recognition.
Due to the inherent complexity associated with valuations and the timing of the acquisition, the amounts below are provisional and subject to adjustment. The fair value of consideration paid was as follows:
Provisional Adjustments Provisional
Cash 5,000 5,000
The preliminary fair value of the assets and liabilities acquired was as follows:
Provisional Adjustments Provisional
Inventory 385 22 407
Prepaid expenses and deposits 10 10
Right of use assets 554 1,150 1,704
Property, plant and equipment 1,172 1,172
Lease liabilities (435 ) (870 ) (1,305 )
Total identifiable net assets acquired 1,686 302 1,988
Goodwill 3,314 (302 ) 3,012
5,000 5,000
Goodwill reflects benefits arising from the acquisition that are not individually identifiable or separately recognizable, including expected operational synergies and future growth opportunities.
As new information is obtained within one year of the date of acquisition, about facts and circumstances that existed at the date of acquisition, the accounting for the acquisition will be revised.
The consolidated financial statements incorporate the operations of the 5 cannabis retail stores located in Alberta and Saskatchewan commencing January 8, 2026. During the period January 8, 2026 to March 31, 2026 the Company recorded revenues of $0.9 million and a net loss of $0.2 million from the 5 cannabis retail stores. Had the First Closing closed on January 1, 2026, management estimates that for the period January 1, 2026, to January 7, 2026, revenue would have increased by $79 thousand and net loss would have increased by $17 thousand. In determining these amounts, management assumes the fair values on the date of acquisition would have been the same as if the acquisition had occurred on January 1, 2026.
The Company incurred costs related to the First Closing of $0.1 million which have been included in transaction costs.
5.Segment information
The Company's reportable segments are organized by business line and are comprised of four reportable segments: liquor retail, cannabis retail, cannabis operations, and investments.
Notes to the Condensed Consolidated Interim Financial Statements
For the three months ended March 31, 2026
(Unaudited, expressed in thousands of Canadian dollars, except where otherwise noted)
Liquor retail includes the sale of wines, beers and spirits through wholly owned liquor stores. Cannabis retail includes the private sale of adult-use cannabis products and accessories through corporate-owned, controlled and franchised retail cannabis stores. Cannabis operations include the cultivation, distribution and sale of cannabis for the adult-use and medical markets domestically and for export, and providing proprietary cannabis processing services, in addition to product development, manufacturing, and commercialization of cannabis consumer packaged goods. Investments include the deployment of capital to investment opportunities. Certain overhead expenses not directly attributable to any operating segment are reported as Corporate .
Cannabis Retail Cannabis Operations Intersegment Eliminations Cannabis Total Liquor Retail Investments Corporate Total
As at March 31, 2026
Total assets 206,508 211,380 417,888 319,076 410,095 167,580 1,314,639
Three months ended March 31, 2026
Net revenue (1) 77,345 29,432 (14,954 ) 91,823 104,083 195,906
Gross profit 20,352 5,802 26,154 26,658 52,812
Operating income (loss) 1,116 (6,942 ) (5,826 ) (3,160 ) 2,038 (2,166 ) (9,114 )
Earnings (loss) before income tax 554 (7,109 ) (6,555 ) (4,572 ) 2,038 (2,319 ) (11,408 )
(1)The Company has eliminated $15.0 million for the three months ended March 31, 2026 of cannabis operations revenue and equal cost of sales associated with sales to provincial boards that are expected to be subsequently repurchased by the Company's licensed retail subsidiaries for resale, at which point the full retail sales revenue will be recognized.
Cannabis Retail Cannabis Operations Intersegment Eliminations Cannabis Total Liquor Retail Investments Corporate Total
As at December 31, 2025
Total assets 219,462 211,625 431,087 324,447 397,537 182,846 1,335,917
Three months ended March 31, 2025
Net revenue (1) 77,540 34,319 (16,417 ) 95,442 109,472 204,914
Gross profit 19,627 9,211 28,838 27,803 56,641
Operating income (loss) (2) 1,327 (6,171 ) (4,844 ) (2,417 ) (1,601 ) (3,191 ) (12,053 )
Earnings (loss) before income tax (2) 774 (6,318 ) (5,544 ) (3,462 ) (1,601 ) (4,100 ) (14,707 )
(1)The Company has eliminated $16.4 million for the three months ended March 31, 2025 of cannabis operations revenue and equal cost of sales associated with sales to provincial boards that are expected to be subsequently repurchased by the Company's licensed retail subsidiaries for resale, at which point the full retail sales revenue will be recognized.
(2)Recast - refer to description below
In 2026, the Company began allocating applicable direct and indirect overhead costs from the corporate segment to each individual operating segment all categorized within general and administrative expenses. The Company has recast the comparative period to illustrate the impact of these allocations had they been done during the prior period.
The following table presents the effect of the adjustments made to operating income (loss) and earnings (loss) before income tax for the periods indicated.
Notes to the Condensed Consolidated Interim Financial Statements
For the three months ended March 31, 2026
(Unaudited, expressed in thousands of Canadian dollars, except where otherwise noted)
Cannabis Retail Cannabis Operations Intersegment Eliminations Cannabis Total Liquor Retail Investments Corporate Total
Three months ended March 31, 2025
Operating income (loss) as previously reported 5,162 (486 ) 4,676 1,980 (1,601 ) (17,108 ) (12,053 )
Adjustment to general and administrative expenses (3,835 ) (5,685 ) (9,520 ) (4,397 ) 13,917
Operating income (loss) as recast 1,327 (6,171 ) (4,844 ) (2,417 ) (1,601 ) (3,191 ) (12,053 )
Earnings (loss) before income tax as previously reported 4,609 (633 ) 3,976 935 (1,601 ) (18,017 ) (14,707 )
Adjustment to general and administrative expenses (3,835 ) (5,685 ) (9,520 ) (4,397 ) 13,917
Earnings (loss) before income tax as recast 774 (6,318 ) (5,544 ) (3,462 ) (1,601 ) (4,100 ) (14,707 )
Geographical disclosure
As at March 31, 2026, the Company had non-current assets related to credit investments in the United States of $395.4 million (December 31, 2025 $385.5 million). For the three months ended March 31, 2026, share of profit of equity-accounted investees related to operations in the United States was a profit of $0.5 million (three months ended March 31, 2025 loss of $4.5 million). All other non-current assets relate to operations in Canada and revenues from external customers relate to operations in Canada.
The Company's biological assets consist of cannabis plants in various stages of vegetation, including plants which have not been harvested. The change in carrying value of biological assets is as follows:
As at March 31, 2026 December 31, 2025
Balance, beginning of year 3,120 1,187
Increase in biological assets due to capitalized costs 4,713 16,082
Net change in fair value of biological assets 46 2,322
Transferred to inventory upon harvest (4,910 ) (16,471 )
Balance, end of period 2,969 3,120
Biological assets are valued in accordance with International Accounting Standard 41 Agriculture and are presented at their fair value less costs to sell up to the point of harvest. This is determined using a model which estimates the expected harvest yield in grams for plants currently being cultivated, and then adjusts that amount for the expected selling price less costs to produce and sell per gram.
The fair value measurements for biological assets have been categorized as Level 3 fair values based on the inputs to the valuation technique used. The Company's method of accounting for biological assets attributes value accretion on a straight-line basis throughout the life of the biological asset from initial cloning to the point of harvest.
The Company estimates the harvest yields for cannabis at various stages of growth. As at March 31, 2026, it is estimated that the Company's biological assets will yield approximately 11,785 kilograms (December 31, 2025 12,189
Notes to the Condensed Consolidated Interim Financial Statements
For the three months ended March 31, 2026
(Unaudited, expressed in thousands of Canadian dollars, except where otherwise noted)
kilograms) of dry cannabis when harvested. During the three months ended March 31, 2026, the Company harvested 8,941 kilograms of dry cannabis (three months ended March 31, 2025 6,736 kilograms).
As at March 31, 2026 December 31, 2025
Retail liquor 77,216 75,145
Retail cannabis 15,772 16,348
Harvested cannabis
Work-in-progress 2,902 2,203
Finished goods 5,434 4,342
Manufactured cannabis
Dried cannabis & biomass 5,397 2,270
Work in progress 13,871 12,577
Finished goods 5,566 5,600
Packaging supplies and consumables 8,824 8,392
134,982 126,877
During the three months ended March 31, 2026, inventories of $141.5 million were recognized in cost of sales as an expense (three months ended March 31, 2025 $148.8 million).
During the three months ended March 31, 2026, the Company recognized inventory write downs of $1.4 million (three months ended March 31, 2025 $0.6 million).

Frequently Asked Questions

What were the total assets as of March 31, 2026?

Total assets were 1,314,639 thousand Canadian dollars.

What was the net loss for the first quarter of 2026?

The net loss for the first quarter of 2026 was 9,911 thousand Canadian dollars.

How much cash and cash equivalents did SNDL have on March 31, 2026?

SNDL had 213,404 thousand Canadian dollars in cash and cash equivalents.

What is SNDL's primary business focus?

SNDL primarily focuses on retailing cannabis products and operating liquor stores.

How did the comprehensive loss change from 2025 to 2026?

Comprehensive loss decreased from 20,285 thousand in 2025 to 6,190 thousand in 2026.

Last updated: Apr 29, 2026